Feb. 11, 2025 – Harrison.ai, a developer of AI-powered medical diagnostic support and workflow solutions, has announced the accelerated expansion of its operations into the United States — a move supported by US$112 million of Series C funding. The funding will also fuel the company’s product roadmap and continued growth in the UK, EMEA and APAC.
Harrison’s technology in radiology and pathology assists clinicians with identifying signs of cancer and other critical illnesses earlier, improving treatment decisions and patient outcomes. It uses AI to analyze CT scans, X-rays and pathology slides, supporting clinicians in detecting and diagnosing medical conditions faster and more accurately.
Harrison.ai aims to address the global shortage of 1.5 million skilled clinicians and the surge in demand for diagnosis impacting both developed and under-developed healthcare systems. In the United States, according to a study by the Association of American Medical Colleges, there are 11 radiologists per 100,000 people. More than two-thirds of the world’s pathologists are distributed across only 10 countries.
“The growing demand for equitable and effective healthcare calls for advanced systems like AI to enhance human diagnostics and address disparities in access to care,” said Dr. Aengus Tran, Harrison.ai Co-Founder and Chief Executive Officer. “Harrison.ai meets this need by developing clinical-grade AI models designed to improve capacity. We look forward to bringing our life-saving technology to healthcare systems in the U.S. and continuing our expansion across the globe."
“Harrison.ai’s ability to harness the rapidly evolving opportunities out of digitization and AI is remarkable and we look forward to supporting their long-term application to the healthcare sector," said Alvin Chan, Portfolio Manager – Direct Equities at Aware Super, one of Australia's largest pension funds managing A$190 billion on behalf of its 1.15 million members.
Harrison.ai solutions are driving a significant improvement through early lung cancer detection within hospital systems. Radiologists using Harrison.ai's technology have seen an over 45% increase in diagnostic accuracy1. Studies indicate that Harrison's AI for chest radiography can aid in the early detection of lung cancer, showing that over 32% of lung cancer cases could have been diagnosed sooner—by an average of 16 months2. Additionally, it has been shown to enhance clinical outcomes by increasing the proportion of cases detected at treatable stages by more than 26%3.
For more information, please visit harrison.ai
References:
[1] Seah JCY, Tang CHM, Buchlak QD, et al. Effect of a comprehensive deep-learning model on the accuracy of chest x-ray interpretation by radiologists: a retrospective, multireader multicase study. Lancet Digital Health. Published 2021. (Averaged across all findings on chest radiographs.)
[2]AIDE study, Alfred Health. 2024. Data on file.
[3] Cameron et al. presented at ECR (European Congress of Radiology) 2024.
November 17, 2025 
